|
|
|
|
| LEADER |
05665nam a2200781 4500 |
| 001 |
ocn904959309 |
| 003 |
OCoLC |
| 005 |
20170124070001.8 |
| 006 |
m o d |
| 007 |
cr ||||||||||| |
| 008 |
150408s2015 enk ob 001 0 eng |
| 010 |
|
|
|a 2015014108
|
| 040 |
|
|
|a DLC
|b eng
|e rda
|e pn
|c DLC
|d N$T
|d DG1
|d BTCTA
|d IDEBK
|d E7B
|d CDX
|d YDXCP
|d COO
|d EBLCP
|d RECBK
|d OCLCF
|d OCLCQ
|d DEBBG
|d K6U
|d GrThAP
|
| 019 |
|
|
|a 905989856
|a 961695642
|a 962722672
|
| 020 |
|
|
|a 9781118892565
|q (ePub)
|
| 020 |
|
|
|a 1118892569
|q (ePub)
|
| 020 |
|
|
|a 9781118892558
|q (Adobe PDF)
|
| 020 |
|
|
|a 1118892550
|q (Adobe PDF)
|
| 020 |
|
|
|a 9781118892572
|
| 020 |
|
|
|a 1118892577
|
| 020 |
|
|
|a 1118892542
|q (cloth)
|
| 020 |
|
|
|a 9781118892541
|q (cloth)
|
| 020 |
|
|
|z 9781118892541
|q (cloth)
|
| 029 |
1 |
|
|a CHBIS
|b 010442471
|
| 029 |
1 |
|
|a CHVBK
|b 334084547
|
| 029 |
1 |
|
|a DEBBG
|b BV042793100
|
| 029 |
1 |
|
|a NZ1
|b 16078501
|
| 029 |
1 |
|
|a DEBBG
|b BV043397613
|
| 035 |
|
|
|a (OCoLC)904959309
|z (OCoLC)905989856
|z (OCoLC)961695642
|z (OCoLC)962722672
|
| 042 |
|
|
|a pcc
|
| 050 |
0 |
0 |
|a RS431.A64
|
| 072 |
|
7 |
|a HEA
|x 039000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 014000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 022000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 112000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 045000
|2 bisacsh
|
| 082 |
0 |
0 |
|a 615.7/98
|2 23
|
| 084 |
|
|
|a SCI007000
|2 bisacsh
|
| 049 |
|
|
|a MAIN
|
| 100 |
1 |
|
|a Lednicer, Daniel,
|d 1929-
|
| 245 |
1 |
0 |
|a Antineoplastic drugs :
|b organic syntheses /
|c Daniel Lednicer.
|
| 264 |
|
1 |
|a Chichester, West Sussex :
|b John Wiley & Sons. Ltd,
|c 2015.
|
| 300 |
|
|
|a 1 online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 520 |
|
|
|a "Antineoplastic Drugs: Organic Syntheses is written to appeal to organic and medicinal chemists in industry and academia. It is beneficial to those composing grant proposals for NCI and related organizations"--
|c Provided by publisher.
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 588 |
0 |
|
|a Print version record and CIP data provided by publisher.
|
| 505 |
0 |
|
|a Title Page; Copyright Page; Contents; Preface; Introduction; Chapter 1 Alkylating Agents; 1.1 bis-Chloroethyl Amines; 1.2 Several Other Chloroethyl Agents; 1.3 Platinum-Based Antineoplastic Agents; 1.4 Miscellaneous Alkylating Agents; References; Chapter 2 Antimetabolites; 2.1 Introduction; 2.2 Folate Antagonists; 2.2.1 Compounds with Glutamate Side Chain; 2.2.2 Compounds Lacking the Glutamate Moiety; 2.2.3 Methoxylated Benzenes; 2.3 Pyrimidines and Purines; 2.3.1 Aglycones; 2.3.2 Saccharide-Linked Compounds; References; Chapter 3 Hormone Blocking Anticancer Drugs; 3.1 Introduction.
|
| 505 |
8 |
|
|a 3.2 Estrogen Antagonists3.2.1 Estrogen Antagonists; 3.2.2 Aromatase Inhibitors; 3.3 Androgen Antagonists; 3.3.1 Non-steroidal Antian drogens; 3.3.2 Steroid Androgen Antagonists; References; Chapter 4 Topoisomerase Inhibitors; 4.1 Introduction; 4.2 Anthracyclines; 4.3 Anthraquinones and Anthrapyrazoles; 4.3.1 Anthraquinones with Two Aminoalkyl Side Chains; 4.3.2 Anthraquinones with a Fused Pyrazole Ring; 4.3.3 Heterocyclic Anthraquinones; 4.4 Camptothecins; 4.4.1 Compounds from Modified Camptothecin; 4.4.2 Camptothecins by Total Synthesis; 4.5 Miscellaneous Topoisomerase Inhibitors; References.
|
| 505 |
8 |
|
|a Chapter 5 Mitotic Inhibitors5.1 Introduction; 5.2 Taxanes; 5.3 Wholly Synthetic Compounds; 5.3.1 Carbocyclic Compounds; 5.3.2 Peptide-Like Inhibitors; 5.3.3 Monocyclic Heterocyclic Inhibitors; 5.3.4 Bicyclic 5:6 Heterocyclic Inhibitors; 5.3.5 Bicyclic 6:6 Heterocyclic Tubulin Inhibitors; References; Chapter 6 Matrix Metalloproteinase Inhibitors; 6.1 Introduction; 6.2 Hydroxamates; 6.2.1 Agents with an Isobutyl Moiety; 6.2.2 A Thiomorpholine; 6.2.3 Sulfamates; 6.2.4 Miscellaneous Compounds; References; Chapter 7 Histone Deacetylase Inhibitors; 7.1 Introduction; 7.2 Hydroxamates.
|
| 505 |
8 |
|
|a 7.3 PhenylenediaminesReferences; Chapter 8 Enzyme Inhibitor, Part I, Tyrosine Kinases; 8.1 Introduction; 8.2 Epidermal Growth Factor Inhibitors; 8.3 VEGF; 8.3.1 Fused Ring Compounds; 8.3.2 Linear Arrays; 8.4 SRC Nonreceptor Tyrosine Kinase; 8.5 PDGF; 8.6 EGF; 8.7 Other TKI; 8.7.1 Linear Arrays; 8.7.2 Compounds with Two Fused Rings; 8.8 Janus Kinase Inhibitors; References; Chapter 9 Enzyme Inhibitors: Part II Additional Targets; 9.1 Serine-Threonine Kinase Inhibitors; 9.2 Additional Enzyme Inhibitors; 9.2.1 Farnesyl Transferase Inhibitors; 9.2.2 Cyclin-Dependent Kinase Inhibitors.
|
| 505 |
8 |
|
|a 9.2.3 Proteasome Inhibitors9.2.4 PARP Inhibitors; 9.2.5 Various Other Enzyme Inhibitors; References; Chapter 10 Miscellaneous Antineoplastic Agents; 10.1 Acyclic; 10.2 Monocyclic; 10.3 Two Linked Rings; 10.4 Rings on a Chain; 10.4.1 Two Rings; 10.4.2 Four and More Rings; 10.5 Fused Rings; 10.5.1 Indoles; 10.5.2 Purine-Like; 10.5.3 Tetralins and a Naphthalene; 10.5.4 Etc.; References; Appendix A; Index of Heterocycle Syntheses; Subject Index; EULA.
|
| 650 |
|
0 |
|a Antineoplastic agents.
|
| 650 |
|
0 |
|a Drugs
|x Synthesis.
|
| 650 |
|
4 |
|a Antimetabolites.
|
| 650 |
|
4 |
|a Antineoplastic agents.
|
| 650 |
|
4 |
|a Cancer.
|
| 650 |
|
4 |
|a Drugs
|x Administration.
|
| 650 |
|
4 |
|a Pharmacognosy.
|
| 650 |
|
7 |
|a SCIENCE
|x Life Sciences
|x Biochemistry.
|2 bisacsh
|
| 650 |
|
7 |
|a Antineoplastic agents.
|2 fast
|0 (OCoLC)fst00810595
|
| 650 |
|
7 |
|a Drugs
|x Synthesis.
|2 fast
|0 (OCoLC)fst00898936
|
| 655 |
|
4 |
|a Electronic books.
|
| 776 |
0 |
8 |
|i Print version:
|a Lednicer, Daniel, 1929-
|t Antineoplastic drugs.
|d Chichester, West Sussex : Wiley, 2015
|z 9781118892541
|w (DLC) 2015008084
|
| 856 |
4 |
0 |
|u https://doi.org/10.1002/9781118892572
|z Full Text via HEAL-Link
|
| 994 |
|
|
|a 92
|b DG1
|
